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Abstract—Catecholamines have been suggested to modulate innate immune responses in experi-
mental settings. The signiﬁcance hereof in the treatment of human septic shock is unknown. We
therefore sought if and how vasopressor/inotropic doses relate to pro-inﬂammatory mediators during
treatment of septic shock. We prospectively studied 20 consecutive septic shock patients. For 3 days
after admission, hemodynamic variables, lactate and plasma levels of interleukins (IL)-6 and 8,
tumor necrosis factor (TNF)-α, and elastase-α1-antitrypsin were measured six hourly. Doses of
vasoactive drugs were recorded. Of the 20 patients, nine died in the intensive care unit. Dobutamine
doses were positively associated and related to TNF-α plasma levels, independently of disease
severity, hemodynamics, and outcome, in multivariable models. Dopamine doses were positively
associated with IL-6, and norepinephrine was inversely associated with IL-8 and TNF-α levels. Our
observations suggest that catecholamines used in the treatment of human septic shock differ in their
potential modulation of the innate immune response to sepsis in vivo. Dobutamine treatment may
contribute to circulating TNF-α and dopamine to IL-6, independently of activated neutrophils.
Conversely, norepinephrine may lack pro-inﬂammatory actions.
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INTRODUCTION
Human septic shock is characterized by release of
pro-inﬂammatory mediators in the host defense against
invading microorganisms, which overwhelms anti-
inﬂammatory mediators, following activation of the
complement system and neutrophils and production of
cytokines such as tumor necrosis factor-alpha (TNF-α)
and interleukins [1–5]. Vasopressor and inotropic drugs
commonly used in the treatment of the syndrome to
augment arterial blood pressure and cardiac function
have been suggested to down- or upregulate innate
immunity in experimental settings with contradicting
results, depending on models, species, challenges, drugs,
and adrenergic receptors [6–22]. It has been suggested
that the use of drugs in the hemodynamic management
of human septic shock may modulate immune responses
in vivo and thereby contribute to their effects on
outcome, even independently of hemodynamics [8, 20,
23, 24]. In experimental human endotoxemia, for
instance, low doses of β-adrenergic dobutamine did
not inhibit circulating innate immune responses, while
epinephrine did [25]. In contrast, in a single randomized
clinical trial, dobutamine was suggested to increase
hepatosplanchnic release of TNF-α in septic shock, as
compared to treatment by enoximone [26]. The interest
for catecholamine-induced modulation of immune
responses has recently been revived by the observation that
endogenous, neutrophil-derived catecholamines play an
important (autocrine) role in the host defense during
experimental sepsis [10, 27]. There are no in vivo data to
supportanyactionofcatecholaminedrugson inﬂammatory
responses.
To further elucidate a potential role in vivo of drug
treatment of human septic shock in modulating innate
immunity, we measured, at six-hourly intervals, pro-
inﬂammatory mediators and recorded vasopressor/ino-
tropic drug doses in 20 consecutive septic shock patients
1Department of Intensive Care and the Institute for Cardiovascular
Research, VU University Medical Center, Amsterdam, The Netherlands
2Department of Surgery, VU University Medical Center, De Boelelaan
1117, 1081, HV Amsterdam, The Netherlands
3To whom correspondence should be addressed at Department of
Surgery, VU University Medical Center, De Boelelaan 1117, 1081,
HV Amsterdam, The Netherlands. E-mail: kjhartemink@hetnet.nl;
E-mail: k.hartemink@vumc.nl
Inﬂammation, Vol. 35, No. 1, February 2012 (# 2011)
DOI: 10.1007/s10753-011-9306-8
206
0360-3997/12/0100-0 0 /0 # 2011 The Author(s). This article is published with open access at Springerlink.com 2 6until 72 h after admission in the intensive care unit
(ICU) and studied longitudinal associations and relations
between variables in the course of disease.
MATERIALS AND METHODS
Patients
We prospectively studied 20 consecutive patients
admitted into the ICU because of septic shock, not
receiving corticosteroid treatment. After obtaining
informed consent in each eligible patient or closest
relative, patients were enrolled within 12 h after
admission. The study had been approved by the Institu-
tional Review Board and the Hospital Committee on
Ethics. Criteria for septic shock were clinical evidence of
infection, temperature above 38.5°C or below 36.0°C,
tachycardia (>90 beats/min), and tachypnea (>20/min) or
necessity for mechanical ventilation. Shock was deﬁned
as a fall in systolic arterial blood pressure below
90 mmHg or by more than 30 mmHg in prior hyper-
tensive patients (in the absence of other causes of
hypotension and despite adequate ﬂuid administration),
or need for administration of vasoactive therapy,
together with at least one sign of inadequate tissue
perfusion (oliguria, mental alterations, hyperlactatemia).
Therapeutic Protocol
Patients were monitored with help of an arterial
catheter for measurement of mean arterial pressure
(MAP; millimeters of mercury) and by a pulmonary
artery catheter (n=14) for measurement of cardiac output
(CO; liters per minute), central venous pressure (CVP;
millimeters of mercury), mean pulmonary artery pres-
sure (millimeters of mercury), and pulmonary artery
occlusion pressure (millimeters of mercury). In the
absence of a pulmonary artery catheter, CVP monitoring
was done with help of a central venous catheter. The
heart rate (beats per minute) was recorded continuously.
Patients were treated by attending physicians not
involved in the study, with help of antibiotics (after
taking appropriate samples for culture), ﬂuids, and
vasoactive drugs through continuous infusions, as
guided by the clinical and hemodynamic response.
Dopamine, dobutamine, and/or norepinephrine were
infused if an increase in forward blood ﬂow or pressure,
respectively, was considered necessary, on clinical
ground. Blood cultures were taken when clinically
indicated. Local specimens for culture were collected
depending on a suspected focus of infection. Blood
cultures were processed using delayed vial entry bottles
for aerobic and anaerobic cultures and Bactec 94/9240
automatic analyzers (Becton-Dickinson, Erembodegem,
Belgium). Bottles were incubated for a maximum of
7 days. If the analyzers showed growth, Gram stains
were prepared and the sensitivity of the organisms for
antibiotics was assessed. Local cultures were processed
according to standardized procedures. Mechanical ven-
tilation was instituted in all but one patient.
Study Protocol
Patient variables, such as age, gender, underlying
disease, source of sepsis, blood, and local culture results,
were recorded. Variables necessary to compute the Acute
Physiology and Chronic Health Evaluation (APACHE)-
II score were recorded and used to estimate severity of
disease in critically ill patients. For 3 days (days 0, 1,
and 2) after admission, patients entered a six-hourly
hemodynamic measurement and blood sampling sched-
ule, at 3.00, 9.00, 15.00, and 21.00 h, as soon as possible
afterenrollment(beginningatday0).Inourunit,pulmonary
artery catheters are removed 72 h after insertion to prevent
catheter-related infection. Hemodynamic variables were
measured with patients in the supine position, after
calibration and zeroing to atmospheric pressure at the mid-
chest level (Viggo-Spectramed,Spectramed,Bilthoven,The
Netherlands; monitor Tramscope
R, Marquette Electronics,
Milwaukee, WI, USA), at end-expiration. For CO
measurements, the average of triplicate injections of
10 mL of D5W at room temperature, at random in the
respiratory cycle, was used. The doses of concomitantly
infused vasoactive drugs were recorded. Hemodynamic
measurements were performed until the pulmonary artery
catheter was taken out by the attending physicians or until
death. Heparin-anticoagulated blood was taken six hourly
from the arterialcatheter to determine plasmalactate levels
and daily to determine creatinine plasma levels. Blood
samples for the determination of plasma levels of pro-
inﬂammatory mediators that are commonly implicated in
the pathogenesis of severe sepsis and shock were obtained
at inclusion and every 6 h. The samples were collected in
tubes containing soybean trypsin inhibitor (100 μg/mL,
ﬁnal concentration), ethylenediaminetetraacetate
(10 mmol/L), and benzamidine (10 mmol/L) to prevent
in vitro activation. All tubes were centrifuged for 10 min at
1,300×g, and aliquots of the plasma were stored
immediately at −70°C until assayed. The length of stay
until discharge from, or death in the ICU, was recorded.
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alive until discharge from the ICU.
Assays
Lactate concentrations (normal value <1.8 mmol/L)
and creatinine (normal value <130 μmol/L) concentra-
tions in plasma were determined with help of an
analyzer (Boehringer-Mannheim Hitachi analyzers 911
and 747, Almere, The Netherlands). Plasma interleukin
(IL)-6 levels were measured by an enzyme-linked
immunosorbent assay using the monoclonal antibody
CLB.IL-6 [3]. Results were related to dose–response
curves obtained with recombinant IL-6 and expressed as
picograms per milliliter. The upper limit of normal is
10 pg/mL. IL-8 was measured by an ELISA in which
antibodies to human recombinant IL-8 (rIL-8; British
Biotechnology Ltd, Oxford, UK) were used. Plates
were coated with a monoclonal antibody against rIL-8
(CLB3.IL-8), and bound IL-8 was detected by a
biotinylated monoclonal antibody. The lower detection
limitis<5pg/mLwithnormalvaluesbelow20pg/mL.The
TNF-α plasma concentration was measured by enzyme
immunoassay (Innogenetics, Zwijnaarde, Belgium), with
an interassay variation of 9% and an intra-assay variation
ranging from 0.8% to 8%; the lower limit of detection is
4 pg/mL and normal values are less than 20 pg/mL.
Elastase-α1-antitrypsin was measured with help of a
radioimmunoassay. Normal values for elastase-α1-anti-
trypsinare <100ng/mL. The intra- and interassayvariation
coefﬁcients for the assays described were <15 and <20%,
respectively.
Calculations and Statistical Analysis
Cardiac index (CI) was calculated as CO/body
surface area (liters per minute per square meter). If
necessary, values were logarithmically transformed to
obtain normal distributions (Kolmogorov–Smirnov test
P>0.05). To study doses of vasopressor/inotropic drugs
in relation to pro-inﬂammatory mediators, generalized
estimating equations (GEE) were done, to take repeated
measurements in the same patients into account; we
entered APACHE-II, MAP, CI, and survival as cova-
riates to adjust for disease severity, hemodynamics, and
outcome. The standardized regression coefﬁcient was
calculated from the regression coefﬁcient multiplied by
the ratio of standard deviations. Differences between
groups in initial, highest, and ﬁnal values for hemody-
namic and pro-inﬂammatory mediators were evaluated
using the non-parametric Mann–Whitney U test. For
dobutamine, the partial correlation coefﬁcient (r), with
patient number and time as covariates, was used to
evaluate relations for pooled data, taking repeated
measurements in the same patients into account, as well
as APACHE-II scores and MAP. Exact P values are
given if >0.001 and were considered statistically
signiﬁcant if <0.05. Values are median and range in text
and tables and mean±standard error of the mean (SEM)
in ﬁgures.
RESULTS
Patient Characteristics
Table 1 describes patient characteristics. Nine
patients (45%) died in the ICU, four of them within
3 days after admission. On day 1, two patients died and
one patient was discharged from the ICU. On day 2, one
Table 1. Patient Characteristics
Age (years) 65 (21–83)
Gender (male/female) 12/8
Underlying disease
COPD 3
Diabetes mellitus 1
Ischemic heart disease 3
Liver cirrhosis 6
Malignancy 7
Renal insufﬁciency 1
Vascular disease 1
Other 4
Source of sepsis
Cholecystitis/cholangitis 2
Diverticulitis 1
Ischemic colitis 1
Mediastinitis 1
Respiratory tract infection 7
Urinary tract infection 4
Genital tract infection 1
Endocarditis 1
Skin 2
APACHE-II score 31 (15–41)
Mechanical ventilation 18
Vasopressor/inotropic treatment 20
Serum creatinine (μmol/L) 177 (49–675)
Renal replacement therapy 6
Duration of observation (h) 72 (6–72)
Length of stay in the ICU (days) 5 (1–29)
Mortality in the ICU 9
Median (range) or number of patients where appropriate
COPD chronic obstructive pulmonary disease, APACHE-II score,
Acute Physiology and Chronic Health Evaluation-II score, ICU
intensive care unit
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ICU. On day 3, one patient died and one patient was
discharged from the ICU, leaving 13 patients in the
study at 72 h after inclusion.
Hemodynamics
As seen in Table 2, patients had a hyperdynamic
circulation with tachycardia, mild hypotension, and
increased CI. Mean arterial pressure was lower and
CVP, and lactate plasma levels were higher in non-
survivors compared to survivors. Non-survivors had
more vasopressor drugs administered compared to
survivors (Table 3). Seven patients had received dobut-
amine at any point of the disease course. Non-survivors
had persistent lactic acidosis.
Pro-inﬂammatory Mediators
IL-6 and IL-8 plasma levels were elevated above
normal in 189 of 195 (97%) and 190 of 195 (97%)
measurements, respectively. TNF-α plasma levels were
elevated above normal in 125 of 160 (78%) and elastase-
α1-antitrypsin in 126 of 195 (65%) measurements.
Inﬂammatory mediators did not differ between survivors
and non-survivors, besides ﬁnal IL-8 levels which were
higher in non-survivors (Table 3). The seven patients
receiving dobutamine in the disease course had higher
TNF-α levels (47 [6–130]pg/mL) than those not receiv-
ing dobutamine (30 [5–301] pg/mL), independently of
APACHE-II scores, MAP, CI, use of other drugs, and
outcome (GEE, P<0.001).
Associations and Relations Between Vasopressor
Doses and Innate Immunity
Figure 1 shows that TNF-α plasma levels fell less
in the seven septic shock patients with dobutamine
compared to the 13 patients without dobutamine. Table 4
shows that plasma levels of TNF-α were higher in those
patients receiving dobutamine than in those not receiving
the drug, independent ofAPACHE-II, MAP, CI, and use of
other drugs. In a multivariable analysis including outcome,
dobutamine doses were positively associated with TNF-α
levels (standardized regression coefﬁcient 0.57, P<0.001),
independentlyofAPACHE-II,hypotension(P=0.031),CI,
and non-survival (P=0.007). The partial correlation coef-
ﬁcient for the relation between TNF-α and dobutamine,
adjustedforrepeatedmeasurementsandAPACHEIIscore,
was 0.38 (P<0.001). Figure 2 shows the relation between
Table 2. Hemodynamic Variables and Vasopressors/Inotropics in the Course of Disease in Outcome Groups
Survivors Non-survivors
P n=11 n=9
HR, beats/min I 118 (105–150) 126 (97–143) 0.73
H 120 (105–176) 130 (100–159) 0.91
L 100 (68–133) 116 (90–130) 0.23
F 107 (61–133) 130 (90–146) 0.22
MAP, mmHg I 70 (53–100) 63 (49–82) 0.27
H 90 (76–100) 80 (49–96) 0.14
L 58 (46–80) 56 (42–72) 0.34
F 76 (70–91) 56 (42–91) 0.03
CVP, mmHg I 8 (4–13) 9 (4–18) 0.30
H1 1 ( 6 –15) 17 (11–21) 0.003
L5 ( 4 –8) 7 (2–18) 0.76
F7 ( 5 –15) 12 (5–22) 0.03
CI, L/min/m
2 I 4.2 (2.1–6.2) 3.4 (1.8–7.2) 0.90
H 4.6 (3.0–6.6) 3.5 (2.4–7.2) 0.56
L 1.6 (2.1–5.2) 2.6 (1.5–6.8) 0.52
F 3.7 (2–6) 3.2 (2.0–6.8) 0.52
Lactate, mmol/L I 1.7 (1.0–5.1) 2.6 (0.9–10.0) <0.001
H 2.0 (1.3–5.1) 3.5 (1.1–11.6) 0.14
L 1.0 (0.7–2.0) 1.9 (0.7–10.0) 0.05
F 1.1 (0.9–2.0) 2.4 (1.0–11.6) 0.01
Median (range) and Mann–Whitney U test
HR heart rate (beats per minute), MAP mean arterial pressure, CVP central venous pressure, CI cardiac index. I initial, H highest, L lowest, F ﬁnal
values in the course of time
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receiving the drug. Other associations were observed
between dopamine doses and IL-6 levels and, inver-
sely, between norepinephrine doses and IL-8 and
TNF-α levels, in some multivariable models. In any
case, none of the vasopressor/inotropic drugs was
associated with elastase-α1-antitrypsin levels.
DISCUSSION
Our observations suggest that, in the treatment of
human septic shock, dobutamine increases circulating
TNF-α and dopamine increases IL-6, independently of
disease severity, hemodynamics, and outcome. Conversely,
norepinephrine may lack pro-inﬂammatory properties. The
differencesbetweendobutamineanddopaminesuggestthat
β and dopaminergic actions were involved, respectively.
The immune alterations, hemodynamic abnormal-
ities, and associations with mortality in our patients
agree with previous reports [1–5, 28]. The positive
association and relation between increases in TNF-α
with increasing doses of dobutamine, a β1- and a weak
α1- and β2-adrenergic receptor agonist, agrees with the
literature suggesting dobutamine- and not enoximone-
induced secretion of TNF-α in isolated hepatocytes and
the hepatosplanchnic region of septic shock patients [7,
26]. It may not agree with the lack of effect of the drug
in the human endotoxemia model [25] and the inhibition
of TNF-α and IL-8 secretion in endotoxin-challenged
isolated (human) monocytes and whole blood by β-
adrenergic receptor actions [9, 13, 15, 20]. Indeed,
circulating leukocytes may not be the source of the TNF-
α increase by dobutamine in our study, since the drug
did not affect levels of neutrophilic elastase-α1-antitryp-
sin. Nevertheless,ourdatamayalsobeinlinewiththepro-
inﬂammatory effect of β-receptor stimulation enhancing
IL-6 and IL-8 production in endotoxin-challenged human
monocytes, whole blood, or endothelial cells in vitro [11,
14, 18]. Moreover, the inverse association between TNF-α
and IL-8 on the one hand and doses of norepinephrine,
an α1,2- and weak β1-agonist, on the other further supports
involvement of β1-receptors in the potentially pro-inﬂam-
matory effect of dobutamine. On the other hand, the data
Table 3. Course of pro-inﬂammatory mediators and drug doses in
outcome groups
Survivors Non-survivors
P n=11 n=9
Inﬂammatory mediators
IL-6, pg/mL
I 293 (17–60,152) 475 (74–161,787) 0.77
H 320 (31–60,152) 761 (197–161,787) 0.55
F4 8 ( 4 –426) 133 (9–161,787) 0.11
IL-8, pg/mL
I 573 (29–10,429) 1,357 (98–12,741) 0.26
H 843 (47–10,458) 1,648 (225–12,741) 0.41
F8 5 ( 7 –1,085) 345 (52–12,741) 0.04
TNF-α, pg/mL
I 49 (17–301) 56 (9–79) 0.46
H 66 (39–301) 56 (19–90) 0.30
F3 0 ( 5 –82) 26 (5–90) 0.94
Elastase-α1-antitrypsin, ng/mL
I 145 (10–716) 131 (12–707) 0.82
H 200 (18–721) 168 (12–905) 0.77
F 98 (18–570) 160 (9–405) 0.60
Drug doses
Dopamine, μg/kg/min
I8 ( 0 –19) 17 (8–22) 0.007
H1 2 ( 0 –19) 19 (8–27) 0.012
F2 ( 0 –16) 19 (5–27) <0.001
Dobutamine, μg/kg/min
I0 ( 0 –21) 0 (0–22) 0.23
H0 ( 0 –21) 12 (0–30) 0.11
F0 ( 0 –5) 5 (0–30) 0.07
Norepinephrine, μg/kg/min
I0 ( 0 –0.16) 0 (0–0.13) 0.15
H 0.05 (0–0.21) 0.24 (0–0.34) 0.004
F0 ( 0 –0.16) 0.14 (0–0.34) 0.002
Median (range) and Mann–Whitney U test
IL-6 (8) interleukin-6 (8), TNF-α tumor necrosis factor alpha, I initial,
H highest, F ﬁnal values in the course of time
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Fig. 1. Course of TNF-α plasma levels in seven septic shock patients
with (ﬁlled circles) and 13 patients without (open squares) dobutamine
infusion at six-hourly time points for the ﬁrst 72 h after inclusion.
Values are mean±SEM; P=0.018 (GEE).
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dobutamine used in previous studies to increase tissue
oxygen delivery to supranormal levels in shock states that
may otherwise be beneﬁcial [20].
Alpha- and β-receptor stimulation may have
opposing effects on TNF-α production in vitro,s i n c e
(endogenous) α2-receptor stimulation may stimulate
TNF-α production by macrophages and Kupffer cells
in some experimental studies [19] but not in others
[17], and in vivo reports are scarce [10, 16, 22]. The
negative associations between TNF-α and IL-8 levels
and norepinephrine dosing, however, suggests an
anti-inﬂammatory effect by norepinephrine via α-
receptor stimulation in septic shock, as suggested
before to occur in septic patients [9]. In contrast,
dopamine treatment was associated with increased IL-
6 levels in most models evaluated, suggesting IL-6
release by endothelium or hepatocytes by D2 recep-
tors, as reported [7, 8, 11, 21]. In any case, the effect
of dopamine, having β1-a n dα1-adrenergic properties
also [8], may have been different from that of
dobutamine and norepinephrine, thereby favoring
predominant dopaminergic effects. Stress or catechol-
amines have also been implicated in the regulation of
IL-10 [8, 9, 14, 18], which we did not measure, so
we cannot exclude that alterations in the latter did
underlie some of the reported associations and
relations. Nevertheless, potentially less pro-inﬂamma-
tory effects of norepinephrine than of dopamine and
Table 4. Generalized Estimating Equations for Pro-Inﬂammatory Mediators and Vasopressor/Inotropic Doses
IL-6 (pg/mL) IL-8 (pg/mL) TNF-α (pg/mL) Elastase-α1-antitrypsin (ng/mL)
BPB P B P B P
Univariable:
Dopamine, μg/kg/min 0.33 0.03 0.48 0.85 0.77
Dobutamine, μg/kg/min 0.19 0.89 0.24 0.01 0.26
Norepinephrine, μg/kg/min 0.57 0.10 –0.30 0.03 0.17
Multivariable:
Dopamine, μg/kg/min 0.33 0.02 0.08 0.74 0.53
Dobutamine, μg/kg/min 0.40 0.80 0.36 <0.001 0.24
Norepinephrine, μg/kg/min 0.70 −0.22 0.02 −0.38 0.04 0.15
APACHE-II −0.35 0.04 0.91 0.06 0.36
Dopamine, μg/kg/min 0.06 0.16 0.85 0.22
Dobutamine, μg/kg/min 0.87 0.69 0.21 0.02 0.27
Norepinephrine, μg/kg/min 0.51 −0.23 0.01 0.10 0.06
MAP −0.28 0.01 0.06 0.18 0.09 0.004
Dopamine, μg/kg/min 0.40 0.01 0.31 0.82 0.64
Dobutamine, μg/kg/min 0.29 0.77 0.60 <0.001 0.43
Norepinephrine, μg/kg/min 0.84 0.07 0.45 0.42
CI, L/min/m
2 0.51 0.002 0.17 0.20 0.02 0.11
Only statistically signiﬁcant regression coefﬁcients are shown
IL-6 (8) interleukin-6 (8), TNF-α tumor necrosis factor-alpha, APACHE-II Acute Physiology and Chronic Health Evaluation-II score, MAP mean
arterial pressure, CI cardiac index, B standardized regression coefﬁcient
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Fig. 2. Scatterplot of pooled data of (logarithmic) TNF-α plasma levels
againstdobutaminedosesgiveninsevenpatientswithsepticshocktreated
with help of dobutamine (any dose), at six-hourly time points for the ﬁrst
72 h after inclusion for observations when dobutamine was given, partial
r=0.29,P=0.06 in survivors (ﬁled circles)a n dr=0.42,P=0.001 in non-
survivors (open squares).
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use of the former in the treatment of shock in the
observational SOAP study [24]. In the study by De
Backer, norepinephrine- and dopamine-treated
patients had similar mortality, but adverse events
were more frequent with the latter [29]. Otherwise,
the lack of potential effect of catecholamines used in
the treatment of septic shock on neutrophil activation
agrees with a previous study in healthy volunteers
[30], but contrasts with aggravation and amelioration
of endotoxin-induced lung injury in rats by α1-a n d
α2-receptor actions on neutrophils, respectively [6].
The limitations of our study include relatively
small number of patients and, by virtue of study
design, evidence on the basis of statistical associations
and relations only, so that results should be interpreted
cautiously. For instance, the predictive value of
circulating pro-inﬂammatory mediators for outcome,
reported by others [1–5], could not be conﬁrmed,
except for IL-8, by our small study and limited period
of observation. On the other hand, analyses were
adjusted for disease severity, hemodynamics, and
outcome, so that the positive relation between dobut-
amine doses and TNF-α levels in the early course of
disease may reﬂect cause effect relations, rather than a
common origin, i.e., severe shock with TNF-α-
induced myocardial depression necessitating dobut-
amine treatment and being associated with demise
[28]. Indeed, this is the ﬁrst study, to our knowledge,
to address the in vivo immune-modulating effect of
various catecholamines used early in the management
of septic shock, independently of disease severity,
hemodynamics, and outcome. Prospective evaluations
of drug effects in septic shock may wish to include
pro-inﬂammatory mediator levels. In fact, our obser-
vations argue in favor of immunosurveillance in future
studies on the hemodynamic management of human
septic shock with help of vasopressor/inotropic drugs.
In conclusion, our prospective observations suggest
that catecholamines used early in the treatment of human
septic shock differ in their potential to modulate the
innate immune response to sepsis in vivo, by differing
adrenergic and dopaminergic receptor stimulation.
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